Disseminated Mycobacterial Infection With Reactive Polyarthritis (Poncet's Disease) During Immune-suppressive Treatment Including Ustekinumab for Pediatric Crohn's Disease.
Journal
The Pediatric infectious disease journal
ISSN: 1532-0987
Titre abrégé: Pediatr Infect Dis J
Pays: United States
ID NLM: 8701858
Informations de publication
Date de publication:
20 Feb 2024
20 Feb 2024
Historique:
medline:
20
2
2024
pubmed:
20
2
2024
entrez:
20
2
2024
Statut:
aheadofprint
Résumé
The incidence of pediatric inflammatory bowel disease is increasing. tumor necrosis factor alpha inhibitors medicines improved the prognosis of affected subjects. Nonetheless, a proportion of patients do not respond or lose response to treatment. Newer biologics, like ustekinumab, have been approved for adults. The pediatric off-label use of these drugs is increasing, despite limited safety evidence. We report a case of disseminated mycobacterial infection (MI) presenting with reactive polyarthritis (Poncet's disease, PD) in a girl with Crohn's disease receiving various immunosuppressants, including ustekinumab. A 12-year-old girl with Crohn's disease was admitted for acute-onset migratory polyarthritis of large and small joints and opioid-resistant pain. She had recently received adalimumab and methotrexate and was currently under treatment with ustekinumab. She was vaccinated with Bacillus Calmette-Guérin and screened for tuberculosis before starting immunosuppressants. Interferon-gamma release assay, Mantoux test and chest computed tomography scan were negative. Disseminated MI with PD was diagnosed following positive cultures for Mycobacterium tuberculosis complex in blood and intestinal biopsies (with negative in synovial fluid and gastric aspirate). Whole-exome sequencing did not identify any genetic susceptibility to MI. Antituberculosis treatment eradicated MI. Children with inflammatory bowel disease receiving combination immunosuppressive treatments including tumor necrosis factor alpha inhibitors and anti-IL-12/23 agents are at higher risk for MI. Disseminated MI should be considered and ruled out in these patients when presenting with pulmonary, extrapulmonary or unusual clinical manifestations, like PD. The collection of multiple specimens (including intestinal biopsies) for mycobacterial culture is recommended when mycobacterial disease is suspected.
Sections du résumé
BACKGROUND
BACKGROUND
The incidence of pediatric inflammatory bowel disease is increasing. tumor necrosis factor alpha inhibitors medicines improved the prognosis of affected subjects. Nonetheless, a proportion of patients do not respond or lose response to treatment. Newer biologics, like ustekinumab, have been approved for adults. The pediatric off-label use of these drugs is increasing, despite limited safety evidence. We report a case of disseminated mycobacterial infection (MI) presenting with reactive polyarthritis (Poncet's disease, PD) in a girl with Crohn's disease receiving various immunosuppressants, including ustekinumab.
CASE REPORT
METHODS
A 12-year-old girl with Crohn's disease was admitted for acute-onset migratory polyarthritis of large and small joints and opioid-resistant pain. She had recently received adalimumab and methotrexate and was currently under treatment with ustekinumab. She was vaccinated with Bacillus Calmette-Guérin and screened for tuberculosis before starting immunosuppressants. Interferon-gamma release assay, Mantoux test and chest computed tomography scan were negative. Disseminated MI with PD was diagnosed following positive cultures for Mycobacterium tuberculosis complex in blood and intestinal biopsies (with negative in synovial fluid and gastric aspirate). Whole-exome sequencing did not identify any genetic susceptibility to MI. Antituberculosis treatment eradicated MI.
CONCLUSIONS
CONCLUSIONS
Children with inflammatory bowel disease receiving combination immunosuppressive treatments including tumor necrosis factor alpha inhibitors and anti-IL-12/23 agents are at higher risk for MI. Disseminated MI should be considered and ruled out in these patients when presenting with pulmonary, extrapulmonary or unusual clinical manifestations, like PD. The collection of multiple specimens (including intestinal biopsies) for mycobacterial culture is recommended when mycobacterial disease is suspected.
Identifiants
pubmed: 38377462
doi: 10.1097/INF.0000000000004277
pii: 00006454-990000000-00759
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors have no funding or conflicts of interest to disclose.
Références
Kucharzik T, Ellul P, Greuter T, et al. ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease. J Crohns Colitis. 2021;15:879–913.
Bonovas S, Fiorino G, Allocca M, et al. Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol. 2016;14:1385–1397.e10.
Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and cochrane overview. Cochrane Database Syst Rev. 2011;2011:CD008794.
Noguera-Julian A, Calzada-Hernández J, Brinkmann F, et al. Tuberculosis disease in children and adolescents on therapy with antitumor necrosis factor-ɑ Agents: a collaborative, multicenter paediatric tuberculosis network European trials group (ptbnet) study. Clin Infect Dis. 2020;71:2561–2569.
Abitbol Y, Laharie D, Cosnes J, et al.; GETAID. Negative screening does not rule out the risk of tuberculosis in patients with inflammatory bowel disease undergoing anti-TNF treatment: a descriptive study on the GETAID cohort. J Crohns Colitis. 2016;10:1179–1185.
Kedia S, Mouli VP, Kamat N, et al. Risk of tuberculosis in patients with inflammatory bowel disease on infliximab or adalimumab is dependent on the local disease burden of tuberculosis: a systematic review and meta-analysis. Am J Gastroenterol. 2020;115:340–349.
Edwards A, Gao Y, Allan RN, et al. Corticosteroids and infliximab impair the performance of interferon-γ release assays used for diagnosis of latent tuberculosis. Thorax. 2017;72:946–949.
Ding NS, Hart A, De Cruz P. Systematic review: predicting and optimising response to anti-TNF therapy in Crohn’s disease - algorithm for practical management. Aliment Pharmacol Ther. 2016;43:30–51.
Sandborn WJ, Feagan BG, Fedorak RN, et al.; Ustekinumab Crohn's Disease Study Group. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology. 2008;135:1130–1141.
Kopylov U, Afif W, Cohen A, et al. Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn’s disease--the McGill experience. J Crohns Colitis. 2014;8:1516–1522.
Rowan CR, Keegan D, Byrne K, et al. Subcutaneous rather than intravenous ustekinumab induction is associated with comparable circulating drug levels and early clinical response: a pilot study. Aliment Pharmacol Ther. 2018;48:333–339.
Buonfrate D, Requena-Mendez A, Angheben A, et al. Severe strongyloidiasis: a systematic review of case reports. BMC Infect Dis. 2013;13:78.
Tjaden NB, Cheng Y, Beierkuhnlein C, et al. Chikungunya beyond the tropics: where and when do we expect disease transmission in Europe?. Viruses. 2021;13:1024.
Errami A, El Baghdadi J, Ailal F, et al. Mendelian susceptibility to mycobacterial disease: an overview. Egypt J Med Hum Genet. 2023;24:7–19.
Noma K, Mizoguchi Y, Tsumura M, et al. Mendelian susceptibility to mycobacterial diseases: state of the art. Clin Microbiol Infect. 2022;28:1429–1434.
Peñafiel Vicuña AK, Yamazaki Nakashimada M, León Lara X, et al. Mendelian susceptibility to mycobacterial disease: retrospective clinical and genetic study in Mexico. J Clin Immunol. 2023;43:123–135.
Taur PD, Gowri V, Pandrowala AA, et al. Clinical and molecular findings in mendelian susceptibility to mycobacterial diseases: experience from India. Front Immunol. 2021;12:631298.
Luo J, Wu SJ, Lacy ER, et al. Structural basis for the dual recognition of IL-12 and IL-23 by ustekinumab. J Mol Biol. 2010;402:797–812.
Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761044lbl.pdfhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761044lbl.pdf: Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761044lbl.pdf; Last accessed on December 3rd, 2023.
Takeuchi I, Arai K, Kyodo R, et al. Ustekinumab for children and adolescents with inflammatory bowel disease at a tertiary children’s hospital in Japan. J Gastroenterol Hepatol. 2021;36:125–130.
Dayan JR, Dolinger M, Benkov K, et al. Real world experience with ustekinumab in children and young adults at a tertiary care pediatric inflammatory bowel disease center. J Pediatr Gastroenterol Nutr. 2019;69:61–67.
Rosh JR, Turner D, Griffiths A, et al. Ustekinumab in paediatric patients with moderately to severely active Crohn’s disease: pharmacokinetics, safety, and efficacy results from UniStar, a phase 1 Study. J Crohns Colitis. 2021;15:1931–1942.
Ghosh S, Long M, Ott E, et al. P553 Active tuberculosis and opportunistic infections: Pooled safety analysis of ustekinumab through up to 5 years across all approved indications. J Crohns Colitis. 2023;17:i681–i682.
Cho SI, Kang S, Kim YE, et al. Ustekinumab does not increase tuberculosis risk: Results from a national database in South Korea. J Am Acad Dermatol. 2020;82:1243–1245.
Cooper AM, Solache A, Khader SA. Interleukin-12 and tuberculosis: an old story revisited. Curr Opin Immunol. 2007;19:441–447.
Philippot Q, Ogishi M, Bohlen J, et al. Human IL-23 is essential for IFN-γ-dependent immunity to mycobacteria. Sci Immunol. 2023;8:eabq5204.
Tsai TF, Chiu HY, Song M, et al. A case of latent tuberculosis reactivation in a patient treated with ustekinumab without concomitant isoniazid chemoprophylaxis in the PEARL trial. Br J Dermatol. 2013;168:444–446.
Errichetti E, Piccirillo A. Latent tuberculosis reactivation in a patient with erythrodermic psoriasis under treatment with ustekinumab and a low dose steroid, despite isoniazid chemoprophylaxis. Eur J Dermatology. 2014;24:508–509.
Lynch M, Roche L, Horgan M, et al. Peritoneal tuberculosis in the setting of ustekinumab treatment for psoriasis. JAAD case reports. 2017;3:230–232.
Sandborn WJ, Rebuck R, Wang Y, et al. Five-year efficacy and safety of ustekinumab treatment in Crohn’s disease: the IM-UNITI trial. Clin Gastroenterol Hepatol. 2022;20:578–590.e4.
Tsai T-F, Ho V, Song M, et al.; PHOENIX 1, PHOENIX 2, ACCEPT, PEARL and Japanese Ustekinumab Study Groups. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. Br J Dermatol. 2012;167:1145–1152.
Sánchez-Moya AI, Daudén E. Peripheral lymph node recurrence of tuberculosis after ustekinumab treatment. Arch Dermatol. 2012;148:1332–1333.
Renoux MC, Dutroncb S, Kollenc L, et al. A case of disseminated tuberculosis in a child with Crohn’s disease after treatment with azathioprine, adalimumab and Ustekinumab. Arch Bronconeumol. 2021;57:552–554.
Choi SJ, Kim MS, Kim ES, et al. Higher risk of tuberculosis in combination therapy for inflammatory bowel disease: a nationwide population-based cohort study in South Korea. Medicine (Baltim). 2020;99:e22897.
Available at: https://www.ema.europa.eu/en/documents/product-information/humira-epar-product-information_en.pdf.
Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–245.
Arimone Y, Bidault I, Dutertre J-P, et al.; Cercle de Réflexion sur l’Imputabilité (CRI). Updating the French method for the causality assessment of adverse drug reactions. Therapie. 2013;68:69–76.
Tilib Shamoun S, Le Friec G, Spinner N, et al. Immune dysregulation in Alagille syndrome: a new feature of the evolving phenotype. Clin Res Hepatol Gastroenterol. 2015;39:566–569.
Shah I, Kalelkar R. Poncet’s disease in an adolescent with abdominal tuberculosis. Paediatr Int Child Health. 2019;39:287–288.
Sharma A, Pinto B, Dogra S, et al. A case series and review of Poncet’s disease, and the utility of current diagnostic criteria. Int J Rheum Dis. 2016;19:1010–1017.
Verma H, Rajvanshi N, Rathaur VK, et al. Poncet’s disease: a case report. J Trop Pediatr. 2021;67:1–5.
Nyo MTL, Ally MMTM, Van Duuren EM, et al. Poncet’s disease in the preclinical phase of rheumatoid arthritis. Case Rep Rheumatol. 20182018;2018:1–5.
Rueda JC, Crepy MF, Mantilla RD. Clinical features of Poncet’s disease. from the description of 198 cases found in the literature. Clin Rheumatol. 2013;32:929–935.
Ferrara G, Giani T, Lieberman SM, et al. Alagille syndrome and chronic arthritis: an international case series. J Pediatr. 2020;218:228–230.e1.
Zeng S, Lin Y, Guo J, et al. Differential diagnosis of Crohn’s disease and intestinal tuberculosis: development and assessment of a nomogram prediction model. BMC Gastroenterol. 2022;22:461.
Available at: https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/1103_GUI_IGRA.pdf. Last accessed December 7th, 2023.
Underwood J, Cresswell F, Salam AP, et al. Complications of miliary tuberculosis: low mortality and predictive biomarkers from a UK cohort. BMC Infect Dis. 2017;17:295.
Calzada-Hernández J, Anton J, Martín de Carpi J, et al. Dual latent tuberculosis screening with tuberculin skin tests and QuantiFERON-TB assays before TNF-α inhibitor initiation in children in Spain. Eur J Pediatr. 2023;182:307–317.
Hussey G, Chisholm T, Kibel M. Miliary tuberculosis in children: a review of 94 cases. Pediatr Infect Dis J. 1991;10:832–836.
Abu-Arja RF, Gonzalez BE, Jacobs MR, et al. Disseminated Bacillus Calmette-Guérin (BCG) infection following allogeneic hematopoietic stem cell transplant in a patient with bare lymphocyte syndrome type II. Transpl Infect Dis. 2014;16:830–837.
Talbot EA, Perkins MD, Silva SF, et al. Disseminated bacille Calmette-Guérin disease after vaccination: case report and review. Clin Infect Dis. 1997;24:1139–1146.
NaserEddin A, Dinur-Schejter Y, Shadur B, et al. Bacillus Calmette-Guerin (BCG) vaccine-associated complications in immunodeficient patients following stem cell transplantation. J Clin Immunol. 2021;41:147–162.
Cheent K, Nolan J, Shariq S, et al. Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn’s disease. J Crohns Colitis. 2010;4:603–605.